Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gefitinib + ONO-7475 + S63845 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gefitinib | Iressa | ZD1839 | EGFR Inhibitor (Pan) 65 EGFR Inhibitor 1st gen 3 | Iressa (gefitinib) is a first-generation EGFR inhibitor that binds EGFR and inhibits downstream signaling, potentially resulting in decreased growth of tumors with EGFR activation (PMID: 26980062, PMID: 25302162, PMID: 15284455). Iressa (gefitinib) is FDA approved for use in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R (FDA.gov). |
ONO-7475 | ONO7475 | AXL Inhibitor 30 FLT3 Inhibitor 69 MERTK Inhibitor 13 TYRO3 Inhibitor 7 | ONO-7475 inhibits AXL, MERTK, FLT3, and TYRO3, potentially leading to reduced growth and increased apoptosis of tumor cells (PMID: 28912176, PMID: 30501104, PMID: 31953310). | |
S63845 | MIK655|MIK-655|MIK 655|S-63845|S 63845 | MCL1 Inhibitor 18 | S63845 (MIK655) is a small molecule drug that binds to and inhibits Mcl1, leading to apoptosis in tumor cells (PMID: 27760111, PMID: 32513939). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|